CAV1 and pachyonychia congenita: Given our in vitro and human clinical outcomes data, we tested the role for Cav-1 in PC tumor initiation and proliferation in vivo, by injecting two different PC cell lines (MIAPaCa-2 and BxPC3) with stable Cav-1 knockdown using two independent shRNA constructs targeting Cav-1 (shCav-1-A in MIAPaCa-2, and shCav-1-B in BxPC3).